Treatment considerations for Behçet's disease

alexandrossfakianakis shared this article with you from Inoreader Treatment considerations for Behçet's disease in the era of COVID‐19: a narrative review Via Wiley: Dermatologic Therapy: Table of Contents Abstract COVID‐19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behçet's disease (BD) is a multi‐systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID‐19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID‐19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and non‐steroidal anti‐inflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID‐19. In cases with COVID‐19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID‐19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.